Study
| Randomized, open-label, phase 3 trial [CheckMate 816] |
| Resectable stage IB to IIIA NSCLC |
| Nivolumab+chemotherapy (n=179) vs chemotherapy (n=179) for 3 cycles followed by surgery |
Efficacy
| 5-year OS: 65.4% vs 55.0% (HR 0.72 [0.52-1.00]) |
| 5-year EFS: 49.2% vs 34.4% (HR 0.68 [0.51-0.91]) |
Safety
| No new safety signals observed |
N Engl J Med. Published online DATE
http://doi.org/10.1056/nejmoa2502931
Reviewed by Elvin Chalabiyev, MD on Sep 3, 2025
